乳腺癌患者皮下植入式静脉输液港的导管相关并发症
Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients.
作者信息
El-Balat Ahmed, Schmeil Iryna, Karn Thomas, Holtrich Uwe, Mavrova-Risteska Loreta, Rody Achim, Youssef Aly, Hanker Lars C
机构信息
Department of Obstetrics and Gynecology, Goethe-University, Frankfurt, Germany
Department of Obstetrics and Gynecology, Goethe-University, Frankfurt, Germany.
出版信息
In Vivo. 2018 Sep-Oct;32(5):1275-1281. doi: 10.21873/invivo.11377.
BACKGROUND/AIM: Totally implanted venous access devices (TIVAD) are increasingly used in the treatment of cancer patients. The aim of this study was to assess the incidence of early and late complications resulting from subcutaneous TIVADs in patients with breast cancer.
MATERIALS AND METHODS
Between 2004 and 2009, we reviewed patients with breast cancer who had a TIVAD placed. Early and late complications, as well as risk factors for TIVAD-associated thrombosis were retrospectively assessed.
RESULTS
A total of 281 patients were included. Complications occurred in 26% of patients, the majority of which were late complications (21.4%.) The development of TIVAD associated thrombosis was the most frequent late complication (16.4%). In the univariate analysis followed by a multivariate model, risk factors for TIVAD associated thrombosis were not identified. Only within the subgroup of metastatic breast cancer patients an increased risk of TIVAD-associated thrombosis of left compared to right venous access was detected (p=0.015).
CONCLUSION
TIVAD implantation done in a gynecological outpatient setting is feasible and safe.
背景/目的：全植入式静脉通路装置（TIVAD）在癌症患者治疗中的应用日益广泛。本研究旨在评估乳腺癌患者皮下TIVAD引发的早期和晚期并发症的发生率。
材料与方法
回顾2004年至2009年间植入TIVAD的乳腺癌患者。对早期和晚期并发症以及TIVAD相关血栓形成的危险因素进行回顾性评估。
结果
共纳入281例患者。26%的患者出现并发症，其中大多数为晚期并发症（21.4%）。TIVAD相关血栓形成是最常见的晚期并发症（16.4%）。在单因素分析及多因素模型分析中，未确定TIVAD相关血栓形成的危险因素。仅在转移性乳腺癌患者亚组中，检测到左侧静脉通路相比右侧静脉通路发生TIVAD相关血栓形成的风险增加（p = 0.015）。
结论
在妇科门诊环境中进行TIVAD植入是可行且安全的。
Zotero 插件